ADICET Bio, Inc. (ACET) Stock AnalysisACETADICET Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Adicet Bio Inc is currently trading at $9.06, with a recent RSI of 57.55 indicating a neutral momentum. The company has a forward P/E of 0, reflecting no current earnings expectations, and a significant net loss of $30.5 million reported in the last fiscal quarter. While there are positive catalysts such as FDA clearance for a Phase 1 study, the ongoing losses and recent downgrades in price targets suggest caution. The main risk is the substantial net loss of $30.5 million, which could impact future funding and operations.

4 analysts cover ACET: 2 rate it Buy, 2 Hold and 0 Sell. The average price target is 29.33.